Aura Biosciences, Inc.

We are a clinical-stage biotechnology company focused on developing precision therapies for solid tumors, designed to preserve organ function. Our primary drug candidate, bel-sar, is in late-stage clinical development for early choroidal melanoma, defined as small choroidal melanoma and/or indeterminate lesions. Bel-sar is also in clinical development for other ocular oncology indications and bladder cancer. We are evaluating bel-sar's safety and efficacy as a potential vision-sparing therapy in our global Phase 3 CoMpass trial for the first-line treatment of adult patients with early choroidal melanoma. We also plan to assess bel-sar for other solid tumors, starting with metastases to the choroid and bladder cancer, and cancers of the ocular surface. In a Phase 2 study (NCT04417530) for first-line treatment of early choroidal melanoma, 22 patients received suprachoroidal (SC) administration of bel-sar and were monitored over a twelve-month follow-up period for tumor control, visual acuity preservation, and tumor growth rate.